睿知中国医院研究地图
候选清单

苏州苏州大学

苏州大学附属第一医院

First Affiliated Hospital of Soochow University

在本站收录的 53 种疾病中,这家医院列在其中 29 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

苏州大学附属第一医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma8 篇牵头论文
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma22 篇牵头论文
  3. 肝细胞癌Hepatocellular carcinoma73 篇牵头论文
  4. 胃癌Stomach cancer90 篇牵头论文牵头 2 项开放试验
  5. 视网膜母细胞瘤Retinoblastoma2 篇牵头论文
  6. 脊索瘤Chordoma2 篇牵头论文
  7. 骨肉瘤Osteosarcoma4 篇牵头论文
  8. 胃肠道间质瘤Gastrointestinal stromal tumour6 篇牵头论文
  9. 神经母细胞瘤Neuroblastoma1 篇牵头论文
  10. 多发性骨髓瘤Multiple myeloma27 篇牵头论文牵头 7 项开放试验
  11. B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia12 篇牵头论文牵头 10 项开放试验
  12. 再生障碍性贫血Aplastic anaemia11 篇牵头论文牵头 2 项开放试验
  13. 噬血细胞性淋巴组织细胞增生症Haemophagocytic lymphohistiocytosis6 篇牵头论文牵头 2 项开放试验
  14. β 地中海贫血Beta thalassaemia1 篇牵头论文
  15. 血友病 AHaemophilia A6 篇牵头论文
  16. 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura5 篇牵头论文牵头 1 项开放试验
  17. 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder10 篇牵头论文
  18. 重症肌无力Myasthenia gravis9 篇牵头论文
  19. 烟雾病Moyamoya disease3 篇牵头论文
  20. 肝豆状核变性Wilson disease2 篇牵头论文
  21. 特发性肺纤维化Idiopathic pulmonary fibrosis3 篇牵头论文
  22. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis1 篇牵头论文
  23. 脊髓性肌萎缩症Spinal muscular atrophy0 篇牵头论文
  24. 法布雷病Fabry disease3 篇牵头论文
  25. 杜氏肌营养不良Duchenne muscular dystrophy2 篇牵头论文
  26. 白塞病Behçet disease0 篇牵头论文
  27. IgA 肾病IgA nephropathy2 篇牵头论文
  28. 原发性胆汁性胆管炎Primary biliary cholangitis2 篇牵头论文
  29. 原发性硬化性胆管炎Primary sclerosing cholangitis1 篇牵头论文

未列出的收录疾病:肝母细胞瘤、尤文肉瘤、非典型溶血性尿毒症综合征、范可尼贫血、IgG4相关性疾病、胆道闭锁、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、肺淋巴管平滑肌瘤病、庞贝病、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 8 篇,占 0.3%。

牵头论文
8
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 2220222023: 2220232024: 2220242025: 002025

苏州有 2 家医院列在鼻咽癌下全国有 183 家医院列在鼻咽癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的鼻咽癌开放试验。

这些数字背后的记录
研究主题放疗技术影像与人工智能诱导/同步化疗
论文中的科室耳鼻喉/头颈外科放疗科

这些论文过半是实验室或动物研究。

牵头的论文8
  1. Expression and functional implications of YME1L in nasopharyngeal carcinoma.2024Cell death & disease免费全文
  2. Prognostic modeling for nasopharyngeal carcinoma (NC) undergoing concurrent chemoradiotherapy using clinical and enhanced MRI-Delta radiomics data: A preliminary study.2024Technology and health care : official journal of the European Society for Engineering and Medicine
  3. Syncope as the initial symptom in a patient with nasopharyngeal carcinoma: a case report.2023BMC cardiovascular disorders免费全文
  4. Overexpressed Gαi1 exerts pro-tumorigenic activity in nasopharyngeal carcinoma.2023Cell death & disease免费全文
  5. CircKIAA0368 Promotes Proliferation, Migration, and Invasion by Upregulating HOXA10 in Nasopharyngeal Carcinoma.2022American journal of rhinology & allergy
  6. Let-7i-5p promotes a malignant phenotype in nasopharyngeal carcinoma via inhibiting tumor-suppressive autophagy.2022Cancer letters
  7. Key genes affecting the progression of nasopharyngeal carcinoma identified by RNA-sequencing and bioinformatic analysis.2021Aging免费全文
  8. Continuous quality improvement of nutrition management during radiotherapy in patients with nasopharyngeal carcinoma.2021Nursing open免费全文
PubMed 以外找到的论文(未计入)13
  1. Salivary metabolomic profiling reveals dynamic metabolic adaptations in nasopharyngeal carcinoma (NPC) patients during radiotherapy2025International Journal of Radiation Research论文
  2. Prediction of Parotid Gland Changes in Radiation-Induced Oral Mucositis of Nasopharyngeal Carcinoma Based on Metabolism-Imaging Bimodal Omics2024International Journal of Radiation Oncology*Biology*Physics论文
  3. Additional file 1 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy2023Figshare数据集
  4. Additional file 2 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy2023Figshare数据集
  5. Additional file 3 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy2023Figshare数据集
  6. Additional file 4 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy2023Figshare数据集
  7. Additional file 5 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy2023Figshare数据集
  8. Additional file 6 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy2023Figshare数据集
  9. Additional file 7 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy2023Figshare数据集
  10. Advances of radiotherapy combined with targeted therapy for nasopharyngeal carcinoma2023Radiation Medicine and Protection论文
  11. Efficacy and safety of penpulimab-containing regimens for advanced malignant solid tumors that have failed immunotherapy: A real-world study.2023Journal of Clinical Oncology会议摘要
  12. Additional file 1 of A two-stage genome-wide association study to identify novel genetic loci associated with acute radiotherapy toxicity in nasopharyngeal carcinoma2022Figshare数据集
  13. Long intergenic non-protein coding RNA 02570 promotes nasopharyngeal carcinoma progression by adsorbing microRNA miR-4649-3p thereby upregulating both sterol regulatory element binding protein 1, and fatty acid synthase2021Figshare数据集

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 22 篇,占 0.8%。

牵头论文
22
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 6620222023: 3320232024: 5520242025: 772025

苏州有 4 家医院列在食管鳞状细胞癌下全国有 192 家医院列在食管鳞状细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。

这些数字背后的记录
研究主题分子标志物与基因影像与人工智能免疫治疗
论文中的科室放疗科肿瘤内科消化/肝病科影像/核医学科
牵头的论文22
  1. RRP9 Promotes Esophageal Squamous Cell Carcinoma Progression through E2F1 Transcriptional Regulation of CDK1.2025Advanced biology免费全文
  2. Organoid-based two-step drug screening for rapid identification of chemotherapy-resistant oesophageal squamous cell carcinoma and alternative therapies.2025Clinical and translational medicine免费全文
  3. Correlation of immune cell subsets in the tumor microenvironment and peripheral blood with immunotherapy response in esophageal squamous cell carcinoma.2025Frontiers in immunology免费全文
  4. Decursin Suppresses Esophageal Squamous Cell Carcinoma Progression via Orchestrated Cell Cycle Deceleration, Apoptotic Activation, and Oncoprotein Degradation.2025International journal of molecular sciences免费全文
  5. A nomogram integrating machine learning-derived CT radiomics and clinical characteristics for prognostic assessment in patients with locally advanced esophageal squamous cell carcinoma treated with definitive chemoradiotherapy with or witho2025Journal of translational medicine免费全文
  6. Improved circulating tumor DNA identification for detection of esophageal squamous cell carcinoma by enzymatic methyl sequencing and hybrid neural network.2025Scientific reports免费全文
  7. Explainable semi-supervised model for predicting invasion depth of esophageal squamous cell carcinoma based on the IPCL and AVA patterns.2025Scientific reports免费全文
  8. Diagnostic Efficacy of Type B Vessels in the Japan Esophageal Society Classification for the Depth of Invasion of Superficial Esophageal Squamous Cell Carcinoma.2024Annali italiani di chirurgia
  9. Integrating 18F-FDG PET/CT radiomics and body composition for enhanced prognostic assessment in patients with esophageal cancer.2024BMC cancer免费全文
  10. First-line treatment with KN046, chemotherapy and palliative radiotherapy for advanced esophageal squamous cell carcinoma: an open-label, dose escalation, and dose expansion phase Ib trial.2024Cancer immunology, immunotherapy : CII免费全文
  11. Spatial transcriptome profiling identifies DTX3L and BST2 as key biomarkers in esophageal squamous cell carcinoma tumorigenesis.2024Genome medicine免费全文
  12. A prognostic nomogram for T3N0M0 esophageal squamous cell carcinoma patients undergoing radical surgery based on computed tomography radiomics and inflammatory nutritional biomarkers.2024Journal of applied clinical medical physics免费全文
  13. RGS16 regulates Hippo-YAP activity to promote esophageal cancer cell proliferation and migration.2023Biochemical and biophysical research communications
  14. Multi-omics analyses reveal spatial heterogeneity in primary and metastatic oesophageal squamous cell carcinoma.2023Clinical and translational medicine免费全文
  15. Peripheral Blood Markers Predictive of Progression-Free Survival in Advanced Esophageal Squamous Cell Carcinoma Patients Treated With PD-1 Inhibitors Plus Chemotherapy as First-Line Therapy.2023Nutrition and cancer
  16. Sesamin exerts anti-tumor activity in esophageal squamous cell carcinoma via inhibition of TRIM44 and NF-κB signaling.2022Chemical biology & drug design
  17. Verbascoside represses malignant phenotypes of esophageal squamous cell carcinoma cells by inhibiting CDC42 via the HMGB1/RAGE axis.2022Human & experimental toxicology
  18. microRNA-497-mediated Smurf2/YY1/HIF2α axis in tumor growth and metastasis of esophageal squamous cell carcinoma.2022Journal of biochemical and molecular toxicology
  19. Esophageal carcinosarcoma comprising undifferentiated pleomorphic sarcoma and squamous cell carcinoma: a case report.2022Journal of cardiothoracic surgery免费全文
  20. Overcoming radio-resistance in esophageal squamous cell carcinoma via hypermethylation of PIK3C3 promoter region mediated by KDM5B loss.2022Journal of radiation research免费全文
  21. Can Lymphovascular Invasion be Predicted by Preoperative Contrast-Enhanced CT in Esophageal Squamous Cell Carcinoma?2022Technology in cancer research & treatment免费全文
  22. Mechanism and Role of the Neuropeptide LGI1 Receptor ADAM23 in Regulating Biomarkers of Ferroptosis and Progression of Esophageal Cancer.2021Disease markers免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. Correlation Between the Efficacy of Neoadjuvant Chemotherapy Combined With Immunotherapy of Operable Thoracic Esophageal Squamous Cell Carcinoma and the Metabolites of Intestinal Flora状态不明NCT05199649牵头方不分期2021-12 启动
  2. Effectiveness of Neoadjuvant Chemotherapy Combined With PD-1 Monoclonal Antibody in the Treatment of Operable Esophageal Squamous Cell Carcinoma状态不明NCT05174325牵头方II期2020-12 启动
  3. Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma状态不明NCT01232374研究中心II期2010-09 启动
PubMed 以外找到的论文(未计入)18
  1. A nomogram integrating machine learning-derived CT radiomics and clinical characteristics for prognostic assessment in patients with locally advanced esophageal squamous cell carcinoma treated with definitive chemoradiotherapy with or witho2025Figshare补充材料
  2. Abstract 1945: High-sensitive gastrointestinal cancers early detection by cell-free DNA targeted methylation sequencing with an innovative modeling approach2025Cancer Research会议摘要
  3. Additional file 1 of A nomogram integrating machine learning-derived CT radiomics and clinical characteristics for prognostic assessment in patients with locally advanced esophageal squamous cell carcinoma treated with definitive chemoradio2025Figshare论文
  4. ESCC-eCura: A Novel Scoring System to Assess Curability after Endoscopic Submucosal Dissection for Superficial Esophageal Squamous Cell Carcinoma2025SSRN Electronic Journal预印本
  5. Kurarinone's synergistic target space and therapeutic promise for esophageal squamous cell carcinoma are revealed by systems pharmacology2025Research Square预印本
  6. Long-Term Outcomes of Dose Escalation in Definitive Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized Phase III Trial2025International Journal of Radiation Oncology*Biology*Physics论文
  7. Regulation and function of the RSK family in colorectal cancer2024Journal of Cancer Metastasis and Treatment论文
  8. Additional file 2 of FBXW7 loss of function promotes esophageal squamous cell carcinoma progression via elevating MAP4 and ERK phosphorylation2023Figshare数据集
  9. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  10. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  11. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  12. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  13. Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma2022Figshare数据集
  14. Additional file 7 of Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma2022Figshare数据集
  15. Exosomal miR-29b-3p derived from cancer- associated fibroblasts contributes to esophageal squamous cell carcinoma cell progression by NAA60 hypomethylation2022Research Square预印本
  16. Postoperative Radiotherapy Involving Tumor Bed with or without Elective Nodal Irradiation in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Multi-Center, Prospective Randomized Phase II Trial2022International Journal of Radiation Oncology*Biology*Physics论文
  17. LncRNA HCP5 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/mTOR signaling2021Figshare数据集
  18. The preliminary efficacy and safety of KN046 plus concurrent chemoradiation therapy in recurrent and metastatic esophageal squamous cell carcinoma.2021Journal of Clinical Oncology会议摘要

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 73 篇,占 0.5%。

牵头论文
73
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 151520212022: 161620222023: 111120232024: 131320242025: 17172025

苏州有 2 家医院列在肝细胞癌下全国有 194 家医院列在肝细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的肝细胞癌开放试验。

这些数字背后的记录
研究主题影像、人工智能与早期发现局部治疗(消融、TACE、HAIC)复发与预后
论文中的科室影像/核医学科普外/肝胆胰外科肿瘤内科
牵头的论文73
  1. Gd-EOB-DTPA-enhanced MRI radiomics and deep learning models for predicting the pathological differentiation degree in hepatocellular carcinoma.2026European journal of radiology
  2. Functional regulatory roles of HNF1B in promoting cell proliferation, migration, invasion and fate decision of hepatocellular carcinoma.2025BMC cancer免费全文
  3. Hepatocellular carcinoma (HCC) and focal nodular hyperplasia (FNH) showing iso- or hyperintensity in the hepatobiliary phase: differentiation using Gd-EOB-DTPA enhanced MRI radiomics and deep learning features.2025BMC medical imaging免费全文
  4. A mutational signature and ARID1A mutation associated with outcome in hepatocellular carcinoma.2025Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  5. Construction of an Oxidative Stress Risk Model to Analyze the Correlation Between Liver Cancer and Tumor Immunity.2025Current cancer drug targets
  6. Clinical characteristics and risk factors of hepatocellular carcinoma development in Budd-Chiari syndrome patients after endovascular treatment.2025Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  7. FBXO42 promotes hepatocellular carcinoma progression via mediating p57Kip2 ubiquitination and degradation.2025European journal of medical research免费全文
  8. CircBRWD1 promotes hepatitis B virus replication and hepatocellular carcinoma progression by regulating the miR-513a-5p/TNPO1 axis.2025Experimental cell research
  9. Survival benefits of different immunotherapies for hepatocellular carcinoma: a meta-analysis highlighting age, gender, etiology, and tumor burden.2025Frontiers in immunology免费全文
  10. KRT80 in hepatocellular carcinoma plays oncogenic role via epithelial-mesenchymal transition and PI3K/AKT pathway.2025IUBMB life
  11. Prexasertib exerts a synergistic effect on the antitumor activity of Lenvatinib through ALOX15-mediated ferroptosis in hepatocellular carcinoma.2025International immunopharmacology
  12. Safety and efficacy of TACE combined with immune checkpoint inhibitors plus molecular targeted therapies in older adults with unresectable hepatocellular carcinoma.2025Journal of cancer research and clinical oncology免费全文
  13. Transarterial chemoembolization combined with percutaneous ethanol injection for the treatment of hepatocellular carcinoma at high-risk areas.2025Journal of cancer research and therapeutics
  14. Heterogeneity Habitats -Derived Radiomics of Gd-EOB-DTPA Enhanced MRI for Predicting Proliferation of Hepatocellular Carcinoma.2025Journal of computer assisted tomography免费全文
  15. Deep Learning Radiopathomics Models Based on Contrast-enhanced MRI and Pathologic Imaging for Predicting Vessels Encapsulating Tumor Clusters and Prognosis in Hepatocellular Carcinoma.2025Radiology. Imaging cancer免费全文
  16. PARK7-driven IGF2BP3-K76 lactylation mediates ferroptosis and HAIC resistance in hepatocellular carcinoma.2025Redox biology免费全文
  17. Development and validation of a prealbumin-bilirubin model for prognostic prediction in intermediate hepatocellular carcinoma undergoing transarterial chemoembolization.2025Scientific reports免费全文
  18. Efficacy and safety of hepatic arterial infusion chemotherapy followed by transarterial embolization for hepatocellular carcinoma.2025Tumori
  19. Emergent TIPS for acute gastroesophageal variceal bleeding in cirrhotic patients with hepatocellular carcinoma.2024Abdominal radiology (New York)
  20. Tim-1-mediated extracellular matrix promotes the development of hepatocellular carcinoma.2024Acta biochimica et biophysica Sinica免费全文
  21. Identification and evaluation of plasma exosome RNA biomarkers for non-invasive diagnosis of hepatocellular carcinoma using RNA-seq.2024BMC cancer免费全文
  22. Gd-EOB-DTPA enhanced MRI nomogram model to differentiate hepatocellular carcinoma and focal nodular hyperplasia both showing iso- or hyperintensity in the hepatobiliary phase.2024BMC medical imaging免费全文
  23. miR-29a-SIRT1-Wnt/β-Catenin Axis Regulates Tumor Progression and Survival in Hepatocellular Carcinoma.2024Biochemical genetics
  24. Long Non-coding RNA LINC00342 Promotes the Proliferation, Invasion, and Migration of Primary Hepatocellular Carcinoma Cells by Regulating the Expression of miRNA-19a-3p, miRNA-545-5p, and miRNA-203a-3p.2024Biochemical genetics
  25. Transarterial Embolization Enhances Programmed Cell Death Ligand 1 Expression and Influences CD8+T Lymphocytes Cytotoxicity in an Orthotopic Hepatocellular Carcinoma Rat Model.2024Cardiovascular and interventional radiology
  26. The Incidences and Related CT Features of Vascular Lake Phenomenon on Angiography Before Chemoembolization.2024Cardiovascular and interventional radiology
  27. Transarterial chemoembolization refractoriness in hepatocellular carcinoma: Chinese College of Interventionalists definition and consensus statement.2024Chinese medical journal免费全文
  28. Radiomic Analysis of Contrast-Enhanced CT Predicts Glypican 3-Positive Hepatocellular Carcinoma.2024Current medical imaging
  29. Cryoablation combined with dual immune checkpoint blockade enhances antitumor efficacy in hepatocellular carcinoma model mice.2024International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  30. Which risk model can better predict hepatocellular carcinoma in hepatitis B patients with an antiviral treatment duration of over 1 year?2024Journal of hepatology
  31. Berberine inhibits the glycolysis and proliferation of hepatocellular carcinoma cells by down-regulating HIF-1α.2024Pakistan journal of pharmaceutical sciences
  32. Machine learning based on gadoxetic acid-enhanced MRI for differentiating atypical intrahepatic mass-forming cholangiocarcinoma from poorly differentiated hepatocellular carcinoma.2023Abdominal radiology (New York)
  33. Circular RNA hsa_circ_0005239 contributes to hepatocellular carcinoma cell migration, invasion, and angiogenesis by targeting the miR-34a-5p/PD-L1 axis.2023Cell biology international
  34. Cuproptosis-related lncRNAs predict the prognosis and immune response in hepatocellular carcinoma.2023Clinical and experimental medicine
  35. The Role of Oxidative Stress in the Development and Therapeutic Intervention of Hepatocellular Carcinoma.2023Current cancer drug targets
  36. Letter re: Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients.2023European journal of cancer (Oxford, England : 1990)
  37. Transarterial chemoembolization combined with molecularly targeted agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a retrospective cohort study.2023Frontiers in immunology免费全文
  38. LncRNA NUTM2A-AS1 aggravates the progression of hepatocellular carcinoma by activating the miR-186-5p/KLF7-mediated Wnt/beta-catenin pathway.2023Human cell
  39. Nomogram Estimating Vessels Encapsulating Tumor Clusters in Hepatocellular Carcinoma From Preoperative Gadoxetate Disodium-Enhanced MRI.2023Journal of magnetic resonance imaging : JMRI
  40. Preoperative Diagnosis of Dual-Phenotype Hepatocellular Carcinoma Using Enhanced MRI Radiomics Models.2023Journal of magnetic resonance imaging : JMRIRCT
  41. LINC00106/RPS19BP1/p53 axis promotes the proliferation and migration of human prostate cancer cells.2023PeerJ免费全文
  42. Global profiling of protein lysine lactylation and potential target modified protein analysis in hepatocellular carcinoma.2023Proteomics
  43. Immune infiltration and clinical significance analyses of the coagulation-related genes in hepatocellular carcinoma.2022Briefings in bioinformatics
  44. hsa_circ_0003410 promotes hepatocellular carcinoma progression by increasing the ratio of M2/M1 macrophages through the miR-139-3p/CCL5 axis.2022Cancer science免费全文
  45. Preoperative CECT-based Radiomic Signature for Predicting the Response of Transarterial Chemoembolization (TACE) Therapy in Hepatocellular Carcinoma.2022Cardiovascular and interventional radiology
  46. LINC02535/miR-30a-5p/GALNT3 axis contributes to lung adenocarcinoma progression via the NF- κ B signaling pathway.2022Cell cycle (Georgetown, Tex.)免费全文
  47. Gd-EOB-DTPA-enhanced MRI radiomics to predict vessels encapsulating tumor clusters (VETC) and patient prognosis in hepatocellular carcinoma.2022European radiology
  48. Hypothyroidism has a protective causal association with hepatocellular carcinoma: A two-sample Mendelian randomization study.2022Frontiers in endocrinology免费全文
  49. Development and Validation of TACE Refractoriness-Related Diagnostic and Prognostic Scores and Characterization of Tumor Microenvironment Infiltration in Hepatocellular Carcinoma.2022Frontiers in immunology免费全文
  50. Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Unresectable Hepatocellular Carcinoma: Efficacy and Systemic Immune Response.2022Frontiers in immunology免费全文
  51. Comprehensive Analysis on the Specific Role and Function of Mitochondrial Inner Membrane Protein MPV17 in Liver Hepatocellular Carcinoma.2022Genetics research免费全文
  52. Alpha-fetoprotein, protein induced by vitamin K absence or antagonist-II, lens culinaris agglutinin-reactive fraction of alpha-fetoprotein alone and in combination for early detection of hepatocellular carcinoma from nonalcoholic fatty live2022Hepatobiliary & pancreatic diseases international : HBPD INT
  53. Re: "Hepatic Artery Infusion Chemotherapy Using Fluorouracil, Leucovorin, and Oxaliplatin versus Transarterial Chemoembolization as Initial Treatment for Locally Advanced Hepatocellular Carcinoma: A Propensity Score-Matching Analysis".2022Journal of vascular and interventional radiology : JVIR
  54. Insights into the Allosteric Effect of SENP1 Q597A Mutation on the Hydrolytic Reaction of SUMO1 via an Integrated Computational Study.2022Molecules (Basel, Switzerland)免费全文
  55. Cytotoxic and anti-tumor effects of 3,4-seco-lupane triterpenoids from the leaves of Eleutherococcus sessiliflorus against hepatocellular carcinoma.2022Natural product research
  56. Immune suppressive function of IL-1α release in the tumor microenvironment regulated by calpain 1.2022Oncoimmunology免费全文
  57. Activating transcription factor 2 promotes the progression of hepatocellular carcinoma by inducing the activation of the WHSC1-mediated TOP2A/PI3K/AKT axis.2022The Kaohsiung journal of medical sciences免费全文
  58. Lysine demethylase 5C epigenetically reduces transcription of ITIH1 that results in augmented progression of liver hepatocellular carcinoma.2022The Kaohsiung journal of medical sciences免费全文
  59. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.2021AJR. American journal of roentgenology
  60. LncRNA PCGEM1 mediates oxaliplatin resistance in hepatocellular carcinoma via miR-129-5p/ETV1 axis in vitro.2021Advances in clinical and experimental medicine : official organ Wroclaw Medical University
  61. RUFY3 promotes the progression of hepatocellular carcinoma through activating NF-κB-mediated epithelial-mesenchymal transition.2021Aging免费全文
  62. Radiomic analysis of Gd-EOB-DTPA-enhanced MRI predicts Ki-67 expression in hepatocellular carcinoma.2021BMC medical imaging免费全文
  63. MicroRNA-92b augments sorafenib resistance in hepatocellular carcinoma via targeting PTEN to activate PI3K/AKT/mTOR signaling.2021Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas免费全文
  64. Integrated I-125 Seed Implantation Combined with Transarterial Chemoembolization for Treatment of Hepatocellular Carcinoma with Main Portal Vein Tumor Thrombus.2021Cardiovascular and interventional radiology
  65. Prognosis Nomogram for Hepatocellular Carcinoma Patients with Portal Vein Invasion Undergoing Transarterial Chemoembolization Plus Sorafenib Treatment: A Retrospective Multicentre Study.2021Cardiovascular and interventional radiology
  66. CT-based radiomics model to distinguish necrotic hepatocellular carcinoma from pyogenic liver abscess.2021Clinical radiology
  67. Silencing PFKP restrains the stemness of hepatocellular carcinoma cells.2021Experimental cell research
  68. Prognostic nomogram for hepatocellular carcinoma patients after transarterial chemoembolization based on des-γ-carboxy prothrombin reactivity and modified Response Evaluation Criteria in Solid Tumors.2021Journal of cancer research and therapeutics
  69. ceRNA network development and tumor-infiltrating immune cell analysis in hepatocellular carcinoma.2021Medical oncology (Northwood, London, England)
  70. miR-760 mediated the proliferation and metastasis of hepatocellular carcinoma cells by regulating HMGA2.2021Pathology, research and practice
  71. cFUT8 promotes liver cancer progression by miR-548c/FUT8 axis.2021Signal transduction and targeted therapy免费全文
  72. Imaging features based on Gd-EOB-DTPA-enhanced MRI for predicting vessels encapsulating tumor clusters (VETC) in patients with hepatocellular carcinoma.2021The British journal of radiology免费全文
  73. Correlation of radiomic features on dynamic contrast-enhanced magnetic resonance with microvessel density in hepatocellular carcinoma based on different models.2021The Journal of international medical research免费全文
中文论文(未计入)7
  1. [Diagnosis and differential diagnosis of small hepatocellular carcinoma in the context of cirrhosis].2025Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  2. [Efficacy and safety of transarterial chemoembolization combined with sintilimab and bevacizumab biosimilar for unresectable hepatocellular carcinoma].2025Zhonghua nei ke za zhi
  3. [Diagnostic value of Gd-EOB-DTPA-enhanced MRI radiomics models for dual-phenotype hepatocellular carcinoma].2024Zhonghua yi xue za zhi
  4. [Construction of a prognostic model for hepatocellular carcinoma based on pyroptosis-related genes].2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  5. [The application value of Gd-EOB-DTPA enhanced MRI based radiomics in the differential diagnosis of iso-or hyperintensity HCC and focal nodular hyperplasia in hepatobiliary phase].2023Zhonghua yi xue za zhiRCT
  6. [The prediction value of enhanced magnetic resonance imaging nomogram model for dual phenotype hepatocellular carcinoma].2022Zhonghua yi xue za zhiRCT
  7. [Value of the application of enhanced CT radiomics and machine learning in preoperative prediction of microvascular invasion in hepatocellular carcinoma].2021Zhonghua yi xue za zhiRCT
它在 ClinicalTrials.gov 上的全部试验(任何状态)6
  1. Evaluate the Effect of Tirazamine on Primary Liver Cancer.已终止NCT06848556研究中心I/II期2021-05 启动
  2. Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)已终止NCT04246177研究中心III期2020-05 启动
  3. Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)已完成NCT03062358研究中心III期2017-04 启动
  4. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)已完成NCT03412773研究中心III期2017-12 启动
  5. The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects已终止NCT03236649研究中心III期2017-09 启动
  6. Efficacy Study of TACE to Treat Hepatocellular Carcinoma After Operation状态不明NCT02631499研究中心IV期2015-12 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 90 篇,占 0.9%。

牵头论文
90
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
2
正在或即将招募
作为研究中心的开放试验
3
由其他机构牵头
每年牵头的论文数
2021: 101020212022: 222220222023: 242420232024: 131320242025: 17172025

苏州有 4 家医院列在胃癌下全国有 211 家医院列在胃癌下

这家医院参与的开放试验 5

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    AI Model for Early Gastric Cancer Diagnosis Using Endoscopic Imaging
    分期
    未注明
    开始
    2026-05
    登记号
    NCT07551466

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:苏州大学附属第一医院苏州

  2. 正在招募
    Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations
    分期
    II期
    开始
    2025-04
    登记号
    NCT07012447

    年龄 14 岁 至 未注明(登记的条件)

    牵头:苏州大学附属第一医院苏州

  3. 正在招募
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    分期
    III期
    开始
    2026-04
    登记号
    NCT07385703

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 64 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南充、南昌、厦门、合肥、天津、太原、安阳、常州、广州、徐州、成都、扬州、承德、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、海口、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛

  4. 正在招募
    AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
    分期
    未注明
    开始
    2023-09
    登记号
    NCT06035250

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、北京、南宁、天津、广州、昆明、沈阳、福州、苏州、郑州、长沙、青岛

  5. 即将招募
    Lymph Node Dissection After Neoadjuvant Therapy for Gastric and EGJ Adenocarcinoma
    分期
    未注明
    开始
    2026-10
    登记号
    NCT07902596

    年龄 18 岁 至 未注明(登记的条件)

    牵头:江苏省人民医院(南医大一附院);另有 6 家列出的医院为研究中心上海、南京、石家庄、苏州、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题腹膜转移与晚期早期发现与内镜影像与人工智能
论文中的科室普外/肝胆胰外科消化/肝病科风湿免疫科肿瘤内科

这些论文过半是实验室或动物研究。

牵头的论文90
  1. Integrating narrative therapy and sleep intervention to enhance recovery, nutritional reconstitution, and 24-month survival following curative gastrectomy: a randomized controlled trial.2026Journal of cancer survivorship : research and practiceRCT
  2. Psychosocial intervention to improve sleep, psychological adjustment, and quality of life in gastric cancer patients undergoing gastrectomy: a randomized controlled trial.2026Journal of cancer survivorship : research and practiceRCT
  3. Combined Effects of Psychological Intervention and Enhanced Nutritional Support on Postoperative Recovery in Gastric Cancer Patients.2026Nutrition and cancerRCT
  4. Combined sleep intervention and nutritional support to enhance postoperative recovery in gastric cancer: a prospective randomized controlled trial.2026Surgical endoscopyRCT
  5. Targeting PTBP3-Mediated Alternative Splicing of COX11 Induces Cuproptosis for Inhibiting Gastric Cancer Peritoneal Metastasis.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  6. Virtual NBI image synthesis using stable diffusion for enhanced recognition of early gastric cancer: a technical validation study.2025Annals of medicine免费全文
  7. Artificial intelligence-assisted diagnosis of early gastric cancer: present practice and future prospects.2025Annals of medicine免费全文
  8. Psychological Interventions and Sleep Improvement for Patients with Gastric Cancer: Effects on Immune Function, Inflammation, and Tumor Progression-A Randomized Controlled Trial.2025Annals of surgical oncologyRCT
  9. The LINC01094/miR-545-3p/SLC7A11 Signaling Axis Promotes the Development of Gastric Cancer by Regulating Cell Growth and Ferroptosis.2025Biochemical genetics免费全文
  10. Artificial intelligence-driven microRNA signature for early detection of gastric cancer: discovery and clinical functional exploration.2025British journal of cancer免费全文
  11. JMJD3 upregulates ALOX5 to drive malignancy and concomitant ferroptosis sensitivity in gastric cancer.2025Cell death & disease免费全文
  12. Tumor exosomal circPTBP3 drives gastric cancer peritoneal metastasis via mesothelial-mesenchymal transition.2025Cell death & disease免费全文
  13. CST1 promoted gastric cancer development by activating the AKT pathway.2025Clinics (Sao Paulo, Brazil)免费全文
  14. Enhancing short-term recovery after gastric cancer surgery: an information-motivation-behavioral skills (IMB) model with nutritional support.2025Future oncology (London, England)RCT免费全文
  15. HIF-1α Promotes the Confined Migration of Gastric Cancer Cells by Modulating Phosphatidylcholine Metabolism.2025Journal of cellular and molecular medicine免费全文
  16. N‑methyladenosine reader YTHDF2‑mediated AC026691.1 degradation promotes gastric cancer cell proliferation, migration and M2 macrophage polarization.2025Molecular medicine reports免费全文
  17. CBX4 Drives Gastric Cancer Progression by Activating β-Catenin Signaling.2025Oncology research免费全文
  18. FBLN2 inhibits gastric cancer proliferation and metastasis via the TGFβ/TGIF2 pathway.2025Pathology, research and practice
  19. Coprevalence of modifiable gastric cancer risk factors and gastric health among Chinese high-risk groups.2025Scientific reports免费全文
  20. Identification of a LncRNA based CeRNA network signature to establish a prognostic model and explore potential therapeutic targets in gastric cancer.2025Scientific reports免费全文
  21. B7-H3 and CD39 Co-Localization in Gastric Cancer: A Potential Prognostic Biomarker and Potential Dual-Target for Immunotherapy.2025Technology in cancer research & treatment免费全文
  22. Predicting esophagojejunal anastomotic leakage in gastric cancer patients after total gastrectomy: Development and assessment of a new predictive nomogram.2024Asian journal of surgery
  23. Glycolysis-related genes predict prognosis and indicate immune microenvironment features in gastric cancer.2024BMC cancer免费全文
  24. Differentially expressed microRNA in prognosis of gastric cancer with Lauren classification.2024Cancer biomarkers : section A of Disease markers免费全文
  25. Exosome-derived proteins in gastric cancer progression, drug resistance, and immune response.2024Cellular & molecular biology letters免费全文
  26. TREM1 facilitates the development of gastric cancer through regulating neutrophil extracellular traps-mediated macrophage polarization.2024Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  27. From mitochondria to tumor suppression: ACAT1's crucial role in gastric cancer.2024Frontiers in immunology免费全文
  28. ITGBL1 promotes anoikis resistance and metastasis in human gastric cancer via the AKT/FBLN2 axis.2024Journal of cellular and molecular medicine免费全文
  29. FOLR2+ macrophage depletion from intestinal metaplasia to early gastric cancer: single-cell sequencing insight into gastric cancer progression.2024Journal of experimental & clinical cancer research : CR免费全文
  30. BUB1 potentiates gastric cancer proliferation and metastasis by activating TRAF6/NF-κB/FGF18 through m6A modification.2024Life sciences
  31. Construction of a TAN-associated risk score model with integrated multi-omics data analysis and clinical validation in gastric cancer.2024Life sciences
  32. Cancer-associated fibroblasts promote proliferation, angiogenesis, metastasis and immunosuppression in gastric cancer.2024Matrix biology : journal of the International Society for Matrix Biology
  33. ARTN-GFRA3 axis induces epithelial-mesenchymal transition phenotypes, migration, and invasion of gastric cancer cells via KRAS signaling.2024Neoplasma
  34. Comparison analysis of two different types of endoscopic resection procedures in small gastric subepithelial tumours originating frommuscularis propria.2024Scandinavian journal of gastroenterology
  35. PRSS2 regulates EMT and metastasis via MMP-9 in gastric cancer.2023Acta histochemica
  36. Identification and validation of crucial lnc-TRIM28-14 and hub genes promoting gastric cancer peritoneal metastasis.2023BMC cancer免费全文
  37. The combination of preoperative fibrinogen-to-albumin ratio and postoperative TNM stage (FAR-TNM) predicts the survival in gastric cancer patients after gastrectomy.2023Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
  38. Feasibility evaluation of hsa_circ_0005480 as an auxiliary diagnostic and prognostic indicator for gastric cancer.2023Biomarkers in medicine
  39. Loss of NDUFS1 promotes gastric cancer progression by activating the mitochondrial ROS-HIF1α-FBLN5 signaling pathway.2023British journal of cancer免费全文
  40. Over-Expression of ARID3B Suppresses Tumor Progression and Predicts Better Prognosis in Patients With Gastric Cancer.2023Cancer control : journal of the Moffitt Cancer Center免费全文
  41. Gastric cancer derived exosomal THBS1 enhanced Vγ9Vδ2 T-cell function through activating RIG-I-like receptor signaling pathway in a N6-methyladenosine methylation dependent manner.2023Cancer letters
  42. Hsa-circ-0052001 promotes gastric cancer cell proliferation and invasion via the MAPK pathway.2023Cancer medicine免费全文
  43. B7-H3 confers stemness characteristics to gastric cancer cells by promoting glutathione metabolism through AKT/pAKT/Nrf2 pathway.2023Chinese medical journal免费全文
  44. Identification of gastric signet ring cell carcinoma based on endoscopic images using few-shot learning.2023Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  45. GADD45B regulates the carcinogenesis process of chronic atrophic gastritis and the metabolic pathways of gastric cancer.2023Frontiers in endocrinology免费全文
  46. Clinical significance of CD155 expression and correlation with cellular components of tumor microenvironment in gastric adenocarcinoma.2023Frontiers in immunology免费全文
  47. Knockdown of LINC01087 inhibits gastric cancer malignant behavior by regulating the miR-135a-5p/CAAP1 axis.2023Functional & integrative genomics
  48. LncRNA RUNX1-IT1 is downregulated in gastric cancer and suppresses the maturation of miR-20a by binding to its precursor.2023Histology and histopathology
  49. miRNA-223-3p regulates ECT2 to promote proliferation, invasion, and metastasis of gastric cancer through the Wnt/β-catenin signaling pathway.2023Journal of cancer research and clinical oncology免费全文
  50. B7-H3 and CD47 co-expression in gastric cancer is a predictor of poor prognosis and potential targets for future dual-targeting immunotherapy.2023Journal of cancer research and clinical oncology免费全文
  51. Integrated multi-dimensional analysis highlights DHCR7 mutations involving in cholesterol biosynthesis and contributing therapy of gastric cancer.2023Journal of experimental & clinical cancer research : CR免费全文
  52. MiR-200/183 family-mediated module biomarker for gastric cancer progression: an AI-assisted bioinformatics method with experimental functional survey.2023Journal of translational medicine免费全文
  53. Expression and clinical significance of PD-L1 and infiltrated immune cells in the gastric adenocarcinoma microenvironment.2023Medicine免费全文
  54. An evaluation of the use of double-curved endoscopes for gastric gastrointestinal stromal tumors.2023Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy
  55. CST1 inhibits ferroptosis and promotes gastric cancer metastasis by regulating GPX4 protein stability via OTUB1.2023Oncogene免费全文
  56. TRIM69 suppressed the anoikis resistance and metastasis of gastric cancer through ubiquitin‒proteasome-mediated degradation of PRKCD.2023Oncogene
  57. Learning curve for endoscopic resection of gastric gastrointestinal stromal tumors: a single-center experience.2023Revista espanola de enfermedades digestivas
  58. Risk factors for conversion from endoscopic resection to laparoscopic resection for gastric gastrointestinal stromal tumors.2023The Journal of international medical research免费全文
  59. The added value of radiomics from dual-energy spectral CT derived iodine-based material decomposition images in predicting histological grade of gastric cancer.2022BMC medical imaging免费全文
  60. Activation of WNT/CTNNB1/TCF7L2 in Epstein-Barr virus-positive gastric cancer regulates epithelial mesenchymal transition.2022Biochemical and biophysical research communications
  61. Circular RNA circ_0001017 Sensitizes Cisplatin-Resistant Gastric Cancer Cells to Chemotherapy by the miR-543/PHLPP2 Axis.2022Biochemical genetics
  62. MicroRNA-642b-3p functions as an oncomiR in gastric cancer by down-regulating the CUB and sushi multiple domains protein 1/smad axis.2022Bioengineered免费全文
  63. Risk Factors and Timing of Additional Surgery after Noncurative ESD for Early Gastric Cancer.2022Canadian journal of gastroenterology & hepatology免费全文
  64. Evaluation of the role of soluble B7-H3 in association with membrane B7-H3 expression in gastric adenocarcinoma.2022Cancer biomarkers : section A of Disease markers免费全文
  65. Gastric cancer-derived exosomal miR-135b-5p impairs the function of Vγ9Vδ2 T cells by targeting specificity protein 1.2022Cancer immunology, immunotherapy : CII免费全文
  66. Cancer-associated fibroblast-released extracellular vesicles carrying miR-199a-5p induces the progression of​ gastric cancer through regulation of FKBP5-mediated AKT1/mTORC1 signaling pathway.2022Cell cycle (Georgetown, Tex.)免费全文
  67. Adenosine triphosphate-based tumor chemosensitivity assay may predict the clinical outcomes of gastric cancer patients receiving taxane-based post-operative adjuvant chemotherapy.2022Chinese medical journal免费全文
  68. Treatment response, survival, and safety profile of camrelizumab plus apatinib regimen as third-line treatment in metastatic gastric cancer patients.2022Clinics and research in hepatology and gastroenterology
  69. Steroid Receptor Coactivator-1 (SRC-1) Promoted Cell Metastasis of Gastric Cancer via VEGFC Activator by NF-κB.2022Critical reviews in eukaryotic gene expression
  70. miR-622 Counteracts the NUAK1-Induced Gastric Cancer Cell Proliferation and the Antioxidative Stress.2022Disease markers免费全文
  71. Roux-en-Y reconstruction alleviates radical gastrectomy-induced colitis via down-regulation of the butyrate/NLRP3 signaling pathway.2022EBioMedicine免费全文
  72. The Deubiquitinating Enzyme USP4 Functions as an Oncoprotein in Gastric Cancer and Mediates NF-κB Signaling by Regulating PRL-3 Expression.2022Frontiers in bioscience (Landmark edition)
  73. A vasculogenic mimicry prognostic signature associated with immune signature in human gastric cancer.2022Frontiers in immunology免费全文
  74. Clinical significance of B7-H3 and HER2 co-expression and therapeutic value of combination treatment in gastric cancer.2022International immunopharmacology
  75. Diagnosis value of miR-181, miR-652, and CA72-4 for gastric cancer.2022Journal of clinical laboratory analysis免费全文
  76. Establishment of a Monoclonal Antibody-Based Enzyme-Linked Immunosorbent Assay to Measure Soluble B7-H5 in Patients with Cancer.2022Journal of immunology research免费全文
  77. Clinical Value of Pepsinogen in the Screening, Prevention, and Diagnosis of Gastric Cancer.2022Laboratory medicine
  78. Billroth II anastomosis maintains SMI and BMI better than Roux-en-Y anastomosis following totally laparoscopic distal gastrectomy: a propensity score-matched study.2022Langenbeck's archives of surgery
  79. PRKAA1, stabilized by FTO in an m6A-YTHDF2-dependent manner, promotes cell proliferation and glycolysis of gastric cancer by regulating the redox balance.2022Neoplasma
  80. LINC00922 acts as a novel oncogene in gastric cancer.2022World journal of surgical oncology免费全文
  81. Evaluating health-related quality of life in gastric cancer patients in Suzhou, China.2021Annals of palliative medicine
  82. Chinese and global burdens of gastric cancer from 1990 to 2019.2021Cancer medicine免费全文
  83. H19 promotes aerobic glycolysis, proliferation, and immune escape of gastric cancer cells through the microRNA-519d-3p/lactate dehydrogenase A axis.2021Cancer science免费全文
  84. Application of Hemocoagulase Bothrops Atrox in the submucosal injection for endoscopic submucosal dissection: a preliminary trial.2021European journal of gastroenterology & hepatologyRCT免费全文
  85. ONECUT2 which is targeted by hsa-miR-15a-5p enhances stemness maintenance of gastric cancer stem cells.2021Experimental biology and medicine (Maywood, N.J.)免费全文
  86. LncRNA-HEIH is a Novel Diagnostic and Predictive Biomarker in Gastric Cancer.2021Genetic testing and molecular biomarkers
  87. LINC02535 promotes cell growth in poorly differentiated gastric cancer.2021Journal of clinical laboratory analysis免费全文
  88. Circular RNA circ_HN1 facilitates gastric cancer progression through modulation of the miR-302b-3p/ROCK2 axis.2021Molecular and cellular biochemistry
  89. Circular RNA hsa_circ_0072309 inhibits the proliferation, invasion and migration of gastric cancer cells via inhibition of PI3K/AKT signaling by activating PPARγ/PTEN signaling.2021Molecular medicine reports免费全文
  90. SIRT5 regulates autophagy and apoptosis in gastric cancer cells.2021The Journal of international medical research免费全文
中文论文(未计入)5
  1. [Risk factors for complications of endoscopic full-thickness resection of upper gastrointestinal submucosal tumors].2023Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  2. [Study of immunophenotypic characteristics, clinicopathological parameters and prognosis in gastric cancer microenvironment].2023Zhonghua yi xue za zhi
  3. [Analysis of efficacy and safety of a new endoscopic anastomosis clip in the treatment of defects after endoscopic full-thickness resection].2023Zhonghua yi xue za zhi
  4. [Gastric adenocarcinoma with enteroblastic differentiation combined with liver metastasis: report of a case].2022Zhonghua bing li xue za zhi = Chinese journal of pathology
  5. [Application of fecal DNA methylation biomarkers detection in gastric cancer screening].2021Zhonghua yi xue za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)11
  1. AI Model for Early Gastric Cancer Diagnosis Using Endoscopic Imaging正在招募NCT07551466牵头方2026-05 启动
  2. Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations正在招募NCT07012447牵头方(推断)II期2025-04 启动
  3. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.正在招募NCT07385703研究中心III期2026-04 启动
  4. Lymph Node Dissection After Neoadjuvant Therapy for Gastric and EGJ Adenocarcinoma即将招募NCT07902596研究中心2026-10 启动
  5. AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy正在招募NCT06035250研究中心2023-09 启动
  6. A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)进行中,不再招募NCT06356311研究中心III期2024-05 启动
  7. A Study of Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in China已完成NCT06585501研究中心2024-08 启动
  8. Phase IIT Trial of SNA014状态不明NCT06646783研究中心早期I期2024-10 启动
  9. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression状态不明NCT04714190研究中心III期2021-03 启动
  10. Enhanced Recovery After Surgery Program for Gastric Cancer: a Multi-center Study状态不明NCT03121729研究中心不分期2017-06 启动
  11. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer已完成NCT01839500研究中心2013-04 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.7%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

苏州有 2 家医院列在视网膜母细胞瘤下全国有 176 家医院列在视网膜母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。

这些数字背后的记录
论文中的科室眼科/神经眼科

打开 PubMed 检索ClinicalTrials.gov

癌症

脊索瘤

Chordoma

2021–2025 年中国大陆作者发表的 105 篇脊索瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 1.9%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

苏州有 1 家医院列在脊索瘤下全国有 84 家医院列在脊索瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.2%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 1120242025: 112025

苏州有 14 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
牵头的论文4
  1. A microsphere-vesicle hybrid system for tumor treatment through enhancement of innate and adaptive immune responses.2026Biomaterials
  2. GD2-mediated impairment of macrophage phagocytosis drives pulmonary metastasis in osteosarcoma.2025Theranostics
  3. Targeting POLRMT by a first-in-class inhibitor IMT1 inhibits osteosarcoma cell growth in vitro and in vivo.2024Cell death & disease
  4. Bioinformatics analysis of key pathways and genes in osteosarcoma development.2023Panminerva medica
早期论文(2016–2020 年)13
  1. TRIM58 Interacts with Pyruvate Kinase M2 to Inhibit Tumorigenicity in Human Osteosarcoma Cells.2020BioMed research international
  2. LINC00612 functions as a ceRNA for miR-214-5p to promote the proliferation and invasion of osteosarcoma in vitro and in vivo.2020Experimental cell research
  3. The Effects of Interleukin-33 (IL-33) on Osteosarcoma Cell Viability, Apoptosis, and Epithelial-Mesenchymal Transition are Mediated Through the PI3K/AKT Pathway.2020Medical science monitor : international medical journal of experimental and clinical research
  4. Long non-coding RNA Taurine upregulated gene 1 promotes osteosarcoma cell metastasis by mediating HIF-1α via miR-143-5p.2019Cell death & disease
  5. Feedback modulation of endothelial cells promotes epithelial-mesenchymal transition and metastasis of osteosarcoma cells by Von Willebrand Factor release.2019Journal of cellular biochemistry
  6. MicroRNA-221 regulates osteosarcoma cell proliferation, apoptosis, migration, and invasion by targeting CDKN1B/p27.2019Journal of cellular biochemistry
  7. NEAT1 induces osteosarcoma development by modulating the miR-339-5p/TGF-β1 pathway.2019Journal of cellular physiology
  8. Transcription factor CEBPB inhibits the proliferation of osteosarcoma by regulating downstream target gene CLEC5A.2019Journal of clinical laboratory analysis
  9. MiR-183 inhibits osteosarcoma cell growth and invasion by regulating LRP6-Wnt/β-catenin signaling pathway.2018Biochemical and biophysical research communications
  10. von Willebrand factor rescued by miR-24 inhibition facilitates the proliferation and migration of osteosarcoma cells in vitro.2018Bioscience reports
  11. DownRegulated SOX4 Expression Suppresses Cell Proliferation, Migration, and Induces Apoptosis in Osteosarcoma In Vitro and In Vivo.2018Calcified tissue international
  12. Mechanisms of oxidative stress, apoptosis, and autophagy involved in graphene oxide nanomaterial anti-osteosarcoma effect.2018International journal of nanomedicine
  13. The lncRNA HNF1A-AS1 is a negative prognostic factor and promotes tumorigenesis in osteosarcoma.2017Journal of cellular and molecular medicine

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 6 篇,占 1.1%。

牵头论文
6
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 2220222023: 3320232024: 1120242025: 002025

苏州有 7 家医院列在胃肠道间质瘤下全国有 240 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录
论文中的科室消化/肝病科普外/肝胆胰外科
牵头的论文6
  1. Comparison analysis of two different types of endoscopic resection procedures in small gastric subepithelial tumours originating frommuscularis propria.2024Scandinavian journal of gastroenterology
  2. An evaluation of the use of double-curved endoscopes for gastric gastrointestinal stromal tumors.2023Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy
  3. Learning curve for endoscopic resection of gastric gastrointestinal stromal tumors: a single-center experience.2023Revista espanola de enfermedades digestivas
  4. Risk factors for conversion from endoscopic resection to laparoscopic resection for gastric gastrointestinal stromal tumors.2023The Journal of international medical research免费全文
  5. The synergistic therapeutic effect of imatinib and protein kinase CK2 Inhibition correlates with PI3K-AKT activation in gastrointestinal stromal tumors.2022Clinics and research in hepatology and gastroenterology
  6. Endoscopic submucosal dissection for ultra-low large rectal stromal tumor after preoperative imatinib therapy: A case report and review.2022Journal of digestive diseases
早期论文(2016–2020 年)2
  1. A comparative study of treatment of gastrointestinal stromal tumors with laparoscopic surgery: a retrospective study.2018Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  2. Application of novel endoloops to close the defects resulted from endoscopic full-thickness resection with single-channel gastroscope: a multicenter study.2017Surgical endoscopy

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.09%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

苏州有 3 家医院列在神经母细胞瘤下全国有 321 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 27 篇,占 1.6%。

牵头论文
27
2021–2025 年
牵头试验
20
任何状态,ClinicalTrials.gov
牵头的开放试验
7
正在或即将招募
作为研究中心的开放试验
10
由其他机构牵头
每年牵头的论文数
2021: 6620212022: 2220222023: 7720232024: 5520242025: 772025

苏州有 2 家医院列在多发性骨髓瘤下全国有 175 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 17

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia
    分期
    早期I期
    开始
    2025-07
    登记号
    NCT06730256

    年龄 18 岁 至 未注明(登记的条件)

    牵头:苏州大学附属第一医院苏州

  2. 正在招募
    Safety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple Myeloma
    分期
    I期
    开始
    2025-07
    登记号
    NCT07652138

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:苏州大学附属第一医院苏州

  3. 正在招募
    Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
    分期
    IV期
    开始
    2024-06
    登记号
    NCT06409702

    年龄 18 岁 至 未注明(登记的条件)

    牵头:苏州大学附属第一医院苏州

  4. 正在招募
    Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients
    分期
    未注明
    开始
    2024-09
    登记号
    NCT06682156

    年龄 18 岁 至 未注明(登记的条件)

    牵头:苏州大学附属第一医院苏州

  5. 正在招募
    Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients
    分期
    I/II期
    开始
    2019-07
    登记号
    NCT04025450

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:苏州大学附属第一医院苏州

  6. 正在招募
    Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma
    分期
    I/II期
    开始
    2016-09
    登记号
    NCT03196414

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:苏州大学附属第一医院苏州

  7. 即将招募
    A Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly Diagnosed Multiple Myeloma Patients With t(11;14) Suitable for Transplantation Using the SonKRd Regimen
    分期
    IV期
    开始
    2026-07
    登记号
    NCT07709884

    年龄 18 岁 至 未注明(登记的条件)

    牵头:苏州大学附属第一医院苏州

  8. 正在招募
    To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma
    分期
    I/II期
    开始
    2026-04
    登记号
    NCT07454187

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 4 家列出的医院为研究中心杭州、苏州、西安、郑州

  9. 正在招募
    A Phase I Study of SHR-3836 in Patients With Multiple Myeloma
    分期
    I期
    开始
    2026-06
    登记号
    NCT07490613

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心苏州

  10. 正在招募
    Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
    分期
    I期
    开始
    2026-03
    登记号
    NCT07529782

    年龄 未注明 至 18 岁(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心北京、天津、杭州、济南、苏州

  11. 正在招募
    Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
    分期
    III期
    开始
    2026-06
    登记号
    NCT07555938

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 13 家列出的医院为研究中心上海、南京、天津、广州、昆明、杭州、武汉、济南、温州、苏州、青岛

  12. 正在招募
    A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma
    分期
    I/II期
    开始
    2026-09
    登记号
    NCT07760454

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心上海、苏州

  13. 正在招募
    A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
    分期
    I/II期
    开始
    2024-07
    登记号
    NCT06083207

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心上海、北京、南京、南宁、天津、徐州、武汉、苏州、西安

  14. 正在招募
    A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
    分期
    III期
    开始
    2024-06
    登记号
    NCT06508983

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心北京、天津、广州、杭州、武汉、苏州、西安、郑州

  15. 正在招募
    A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
    分期
    I/II期
    开始
    2023-10
    登记号
    NCT06049290

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 20 家列出的医院为研究中心上海、北京、厦门、太原、宁波、广州、杭州、武汉、沈阳、海口、深圳、温州、芜湖、苏州、西安、贵阳、郑州、长春、青岛

  16. 正在招募
    A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
    分期
    III期
    开始
    2022-11
    登记号
    NCT05623020

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、南京、天津、广州、杭州、武汉、温州、福州、苏州、长春

  17. 正在招募
    A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
    分期
    II期
    开始
    2021-02
    登记号
    NCT04634552

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心北京、天津、苏州、西安

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题诊断、微小残留病与危险分层CAR-T 与细胞治疗干细胞移植
论文中的科室影像/核医学科病理/检验科神经内科
牵头的论文27
  1. Poor prognosis of newly diagnosed multiple myeloma patients with 1p32.3 deletion in single monoallelic deletion and/or in main clone.2025British journal of haematology免费全文
  2. Redefining multiple myeloma treatment: Advances, challenges, and future directions in immunotherapy.2025Chinese medical journal免费全文
  3. A rare case of concurrent JAK2V617F-positive essential thrombocythemia, multiple myeloma, and colorectal adenocarcinoma.2025Indian journal of pathology & microbiology
  4. A 2D-STI echocardiographic diagnostic model established for cardiac amyloidosis complicated with multiple myeloma.2025International journal of cardiology
  5. Effect of oral care models on the prevention of oral mucositis induced by high-doses of melphalan in patients undergoing ASCT.2025Medicine免费全文
  6. Application of individualized low-protein diet nursing for managing multiple myeloma patients with renal impairment.2025Medicine免费全文
  7. Landscapes of immunoglobulin heavy-chain gene repertoire and its cytogenetic abnormalities in Chinese patients with multiple myeloma.2025Scientific reports免费全文
  8. Effective Treatment with Venetoclax and Hypomethylating Agents for the Coexistence of Multiple Myeloma and Acute Myeloid Leukemia: A Case Report and Literature Review.2024Annals of clinical and laboratory science
  9. MRI-based bone marrow radiomics for predicting cytogenetic abnormalities in multiple myeloma.2024Clinical radiology
  10. Successful treatment with bortezomib, thalidomide and dexamethasone in plasma cell myeloma post-bone marrow transplant.2024Leukemia & lymphoma
  11. Quantitative assessment of bone marrow infiltration and characterization of tumor burden using dual-layer spectral CT in patients with multiple myeloma.2024Radiology and oncology免费全文
  12. Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.2024The New England journal of medicineRCT
  13. Autologous stem cell transplantation in multiple myeloma patients with renal impairment.2023Annals of hematology
  14. Discriminating minimal residual disease status in multiple myeloma based on MRI: utility of radiomics and comparison of machine-learning methods.2023Clinical radiology
  15. Increased expression of CEP72 predicts poor prognosis in multiple myeloma.2023International journal of laboratory hematology
  16. Nursing care of patients with relapsed and refractory multiple myeloma treated with B-cell mature antigen-targeted universal chimeric antigen receptor T cells.2023Medicine免费全文
  17. Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma.2023Nature communications免费全文
  18. Apparent diffusion coefficient measurements of bone marrow infiltration patterns in multiple myeloma for the assessment of tumor burden - a feasibility study.2023Radiology and oncology免费全文
  19. Cystatin C and eGFRCKD-EPI-CysC: novel biomarkers for renal impairment diagnosis and two-year progression-free survival in multiple myeloma.2023Scandinavian journal of clinical and laboratory investigation
  20. Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma.2022American journal of hematology
  21. Successful eradication of central nervous system infiltration of primary plasma cell leukemia by temozolomide.2022Annals of hematology
  22. Pulsatilla saponin A Induces Apoptosis and Differentiation of Myeloma Cells.2021Anti-cancer agents in medicinal chemistry
  23. C3a and C5a facilitates the metastasis of myeloma cells by activating Nrf2.2021Cancer gene therapy
  24. Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and/or refractory myeloma.2021Cancer medicine免费全文
  25. Inhibition of the Otub1/c-Maf axis by the herbal acevaltrate induces myeloma cell apoptosis.2021Cell communication and signaling : CCS免费全文
  26. Case Report: Reversible Neurotoxicity and a Clinical Response Induced by BCMA-Directed Chimeric Antigen Receptor T Cells Against Multiple Myeloma With Central Nervous System Involvement.2021Frontiers in immunology免费全文
  27. Quantitative evaluation of bone marrow infiltration using dual-energy spectral computed tomography in patients with multiple myeloma.2021Journal of X-ray science and technology
中文论文(未计入)19
  1. [Renal response and prognosis of newly diagnosed patients with multiple myeloma with renal impairment applying VRD and autologous hematopoietic stem cell transplantation].2025Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  2. [Effect of Recombinant Human Thrombopoietin on Platelet Reconstitution after Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma].2024Zhongguo shi yan xue ye xue za zhi
  3. [Interpretation of minimal residual disease for response evaluation in guidelines for the diagnosis and management of multiple myeloma in China (2024 revision)].2024Zhonghua nei ke za zhi
  4. [Interpretation of risk stratification in guidelines for the diagnosis and management of multiple myeloma in China (2024 revision)].2024Zhonghua nei ke za zhi
  5. [Efficacy and safety of VRD regimen of autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma].2023Zhonghua nei ke za zhi
  6. [Clinical significance and pathogenesis analysis of Moesin in multiple myeloma].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  7. [Efficacy and safety of bendamustine combined with pomalidomide and dexamethasone in patients with relapsed and refractory multiple myeloma].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  8. [Comparison of next-generation flow cytometry and next-generation sequencing in the assessment of minimal residual disease in multiple myeloma].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  9. [The Role of Whole Body DWI in the Evaluation of Bone Disease in Multiple Myeloma].2022Zhongguo shi yan xue ye xue za zhi
  10. [Efficacy of total oral regimens containing ixazomib in patients with relapsed and refractory multiple myeloma].2022Zhonghua nei ke za zhi
  11. [Efficacy and safety of lenalidomide combined with bortezomib and dexamethasone induction therapy in newly diagnosed patients with multiple myeloma].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  12. [Multiple myeloma with chromothripsis: three cases report].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  13. [A clinical retrospective analysis of newly diagnosed multiple myeloma patients with systemic light chain amyloidosis].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  14. [The expression level of secretory mature B cell surface antigen in primary diagnosed multiple myeloma and its clinical significance].2022Zhonghua yi xue za zhi
  15. [Preliminary exploration of the metabolic profile and metabolic pathways in newly diagnosed multiple myeloma].2022Zhonghua zhong liu za zhi [Chinese journal of oncology]
  16. [Application of Conditioning Regimen with Busulfan and Cyclophosphamide in Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma].2021Zhongguo shi yan xue ye xue za zhi
  17. [The Effects of Chidamide Combined with Anti-myeloma Drugs on the Proliferation and Apoptosis of Myeloma Cells].2021Zhongguo shi yan xue ye xue za zhi
  18. [Clinical Features and Prognostic Factors of Patients with Multiple Myeloma].2021Zhongguo shi yan xue ye xue za zhi
  19. [Characteristics of immunoglobulin heavy-chain gene clonal rearrangements by next-generation sequencing of patients with multiple myeloma].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)49
  1. A Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly Diagnosed Multiple Myeloma Patients With t(11;14) Suitable for Transplantation Using the SonKRd Regimen即将招募NCT07709884牵头方IV期2026-07 启动
  2. Safety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple Myeloma正在招募NCT07652138牵头方I期2025-07 启动
  3. A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia正在招募NCT06730256牵头方早期I期2025-07 启动
  4. Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients正在招募NCT06682156牵头方2024-09 启动
  5. Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection正在招募NCT06409702牵头方IV期2024-06 启动
  6. Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients正在招募NCT04025450牵头方I/II期2019-07 启动
  7. Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma正在招募NCT03196414牵头方I/II期2016-09 启动
  8. An Open Label, Single-arm Clinical Study Evaluating the Safety and Efficacy of ICI201 Infusion in Relapsed/Refractory Multiple Myeloma已撤回NCT05980507牵头方I期2023-10 启动
  9. Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients状态不明NCT05855122牵头方IV期2023-04 启动
  10. CT0594CP CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia状态不明NCT05822037牵头方不分期2023-04 启动
  11. This is an Open-label, Single Arm Study to Evaluate the Safety and Tolerability of Treatment With CT0591CP in Patients With Relapsed and/or Refractory Multiple Myeloma.状态不明NCT05486975牵头方早期I期2022-08 启动
  12. Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y001#已完成NCT05270928牵头方I期2022-04 启动
  13. Cohort Construction and Prognostic Model Construction for Multiple Myeloma进行中,不再招募NCT06366802牵头方2022-05 启动
  14. A Study to Access the Safety and Efficacy of CT0590 in Patients With Relapsed and/or Refractory Multiple Myeloma状态不明NCT05066022牵头方不分期2021-10 启动
  15. Dose Exploration Study OF JWCAR129, BCMA-Targeted CART for RRMM状态不明NCT04677452牵头方I期2020-12 启动
  16. A Study of the Bortezomib, Lenalidomide, and Dexamethasone Regimen for the Treatment of Newly Diagnosed Multiple Myeloma Patients已完成NCT07206810牵头方2018-08 启动
  17. Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT进行中,不再招募NCT03455972牵头方I/II期2018-02 启动
  18. Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients状态不明NCT04287660牵头方III期2017-10 启动
  19. PDD vs PAD to Treat Initially Diagnosed MM状态不明NCT02577783牵头方IV期2015-10 启动
  20. Study of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma in China状态不明NCT01812096牵头方I/II期2014-05 启动
  21. Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma正在招募NCT07555938研究中心III期2026-06 启动
  22. A Phase I Study of SHR-3836 in Patients With Multiple Myeloma正在招募NCT07490613研究中心I期2026-06 启动
  23. To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma正在招募NCT07454187研究中心I/II期2026-04 启动
  24. Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma正在招募NCT07529782研究中心I期2026-03 启动
  25. A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma正在招募NCT07760454研究中心I/II期2026-09 启动
  26. A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients正在招募NCT06508983研究中心III期2024-06 启动
  27. A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma正在招募NCT06083207研究中心I/II期2024-07 启动
  28. A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma正在招募NCT06049290研究中心I/II期2023-10 启动
  29. A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant正在招募NCT05623020研究中心III期2022-11 启动
  30. A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma正在招募NCT04634552研究中心II期2021-02 启动
  31. Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT06158841研究中心III期2024-05 启动
  32. A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)进行中,不再招募NCT06464991研究中心III期2024-03 启动
  33. A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment进行中,不再招募NCT05455320研究中心III期2022-10 启动
  34. A Study of Daratumumab进行中,不再招募NCT05438043研究中心III期2022-12 启动
  35. A Study of NINLARO® in Chinese Adults With Multiple Myeloma进行中,不再招募NCT05013190研究中心2021-10 启动
  36. APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma状态不明NCT04674514研究中心I/II期2021-04 启动
  37. A Study of Ninlaro in Real World Clinical Practice in China已完成NCT04328662研究中心2020-05 启动
  38. Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)状态不明NCT03975907研究中心I/II期2019-06 启动
  39. A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma已完成NCT03944057研究中心II期2019-09 启动
  40. TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma已完成NCT03952091研究中心III期2019-03 启动
  41. A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.进行中,不再招募NCT03539744研究中心III期2018-10 启动
  42. A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma已终止NCT03215030研究中心I/II期2017-10 启动
  43. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)已完成NCT03217812研究中心III期2017-11 启动
  44. Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma已完成NCT03029234研究中心III期2017-03 启动
  45. A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma已完成NCT03234972研究中心III期2017-11 启动
  46. An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants已终止NCT02761187研究中心2016-07 启动
  47. Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma已完成NCT01818752研究中心III期2013-07 启动
  48. Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year已完成NCT02348528研究中心II期2012-09 启动
  49. Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma已完成NCT01593410研究中心II期2010-08 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

B 细胞急性淋巴细胞白血病

B-cell acute lymphoblastic leukaemia

2021–2025 年中国大陆作者发表的 225 篇B 细胞急性淋巴细胞白血病 PubMed 英文论文中,这家医院牵头了 12 篇,占 5.3%。

牵头论文
12
2021–2025 年
牵头试验
19
任何状态,ClinicalTrials.gov
牵头的开放试验
10
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 3320232024: 7720242025: 222025

苏州有 2 家医院列在B 细胞急性淋巴细胞白血病下全国有 88 家医院列在B 细胞急性淋巴细胞白血病下

这家医院参与的开放试验 10

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    BEBT-908 in MEF2D-Rearranged Relapsed/Refractory or MRD-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
    分期
    I期
    开始
    2026-09
    登记号
    NCT07854652

    年龄 14 岁 至 75 岁(登记的条件)

    牵头:苏州大学附属第一医院苏州

  2. 正在招募
    Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy
    分期
    II期
    开始
    2025-05
    登记号
    NCT06985485

    年龄 15 岁 至 未注明(登记的条件)

    牵头:苏州大学附属第一医院苏州

  3. 正在招募
    Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
    分期
    II期
    开始
    2025-04
    登记号
    NCT07564453

    年龄 15 岁 至 65 岁(登记的条件)

    牵头:苏州大学附属第一医院苏州

  4. 正在招募
    RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.
    分期
    II期
    开始
    2024-02
    登记号
    NCT06250959

    年龄 15 岁 至 65 岁(登记的条件)

    牵头:苏州大学附属第一医院苏州

  5. 正在招募
    Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL
    分期
    II期
    开始
    2024-04
    登记号
    NCT06393985

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:苏州大学附属第一医院苏州

  6. 正在招募
    Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL
    分期
    I期
    开始
    2024-04
    登记号
    NCT06507514

    年龄 15 岁 至 65 岁(登记的条件)

    牵头:苏州大学附属第一医院苏州

  7. 正在招募
    Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
    分期
    早期I期
    开始
    2024-12
    登记号
    NCT06696833

    年龄 14 岁 至 未注明(登记的条件)

    牵头:苏州大学附属第一医院苏州

  8. 正在招募
    CAV Regimen for R/R Ph- B-ALL
    分期
    不分期
    开始
    2022-10
    登记号
    NCT05657652

    年龄 15 岁 至 70 岁(登记的条件)

    牵头:苏州大学附属第一医院苏州

  9. 即将招募
    U96-CAR-T-Cells For R/R B-ALL
    分期
    I期
    开始
    2026-07
    登记号
    NCT07511426

    年龄 18 岁 至 未注明(登记的条件)

    牵头:苏州大学附属第一医院苏州

  10. 即将招募
    Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia
    分期
    早期I期
    开始
    2024-09
    登记号
    NCT06559644

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:苏州大学附属第一医院苏州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题儿童抗体与靶向药物CAR-T 与细胞治疗
牵头的论文12
  1. Shorter Duration of Blinatumomab Administration to 14 Days Has Same Efficacy and Safety Profile in Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: A Retrospective Single-Center Study.2025Acta haematologica
  2. A phase 2 trial of a "sandwich" strategy: Sequential CD22/CD19 chimeric antigen receptor T-cells therapy combined with autologous hematopoietic stem cell transplantation in patients with Philadelphia chromosome-negative B-cell acute lymphob2025Cancer免费全文
  3. Genetic and clinical characteristics of acute B-cell lymphoblastic leukemia with MEF2D fusions and report of two novel MEF2D rearrangements.2024Annals of hematology
  4. Safety and efficacy of blinatumomab as bridge-to-transplant for B-cell acute lymphoblastic leukemia in first complete remission with no detectable minimal residual disease.2024Blood cancer journal免费全文
  5. Reduced-dose chemotherapy followed by blinatumomab in induction therapy for newly diagnosed B-cell acute lymphoblastic leukemia.2024Cancer medicine免费全文
  6. Rituximab potentially improves clinical outcomes of CAR-T therapy for r/r B-ALL via sensitizing leukemia cells to CAR-T-mediated cytotoxicity and reducing CAR-T exhaustion.2024Cellular oncology (Dordrecht, Netherlands)免费全文
  7. Real-world evidence on treatment pattern, effectiveness, and safety of blinatumomab in Chinese patients with B-cell acute lymphoblastic leukemia.2024Investigational new drugs免费全文
  8. Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial.2024Journal of hematology & oncology免费全文
  9. Decitabine consolidation after CD19/CD22 CAR-T therapy as a novel maintenance treatment significantly improves survival outcomes in relapsed/refractory B-ALL patients.2024Leukemia research
  10. Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?2023Blood cancer journal免费全文
  11. CD19/CD22 dual-targeting chimeric antigen receptor T-cell therapy bridging to allogeneic haematopoietic stem cell transplantation for B-cell acute lymphoblastic leukaemia delays platelet recovery and increases risks of cytomegalovirus and E2023Clinical and translational medicine免费全文
  12. Case Report: Blinatumomab therapy for the treatment of B-cell acute lymphoblastic leukemia patients with central nervous system infiltration.2023Frontiers in immunology免费全文
中文论文(未计入)4
  1. [Clinical analysis of 7 cases of acute B cell lymphoblastic leukemia with t (17;19) (q21-22;p13)/TCF3-HLF fusion].2024Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  2. [Clinical efficacy and safety of blinatumomab bridging CAR-T cell therapy in the treatment of patients with adult acute B-cell lymphoblastic leukemia].2024Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  3. [Effect of MXRA7 on the Biological Functions of Acute B Lymphoblastic Leukemia Cell Line REH].2023Zhongguo shi yan xue ye xue za zhi
  4. [Ph-like B-cell acute lymphoblastic leukemia with ZEB2-JAK2 fusion gene positivity: a case report].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)23
  1. U96-CAR-T-Cells For R/R B-ALL即将招募NCT07511426牵头方I期2026-07 启动
  2. BEBT-908 in MEF2D-Rearranged Relapsed/Refractory or MRD-Positive B-Cell Precursor Acute Lymphoblastic Leukemia正在招募NCT07854652牵头方I期2026-09 启动
  3. Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy正在招募NCT06985485牵头方II期2025-05 启动
  4. Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia正在招募NCT07564453牵头方II期2025-04 启动
  5. Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia即将招募NCT06559644牵头方早期I期2024-09 启动
  6. Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL正在招募NCT06507514牵头方I期2024-04 启动
  7. Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia正在招募NCT06696833牵头方早期I期2024-12 启动
  8. Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL正在招募NCT06393985牵头方II期2024-04 启动
  9. CAV Regimen for R/R Ph- B-ALL正在招募NCT05657652牵头方不分期2022-10 启动
  10. Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL已暂停NCT06985498牵头方II期2025-06 启动
  11. CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL).状态不明NCT06078306牵头方II期2024-04 启动
  12. ThisCART19A Bridging to alloHSCT for R/R B-ALL状态不明NCT05679687牵头方I期2022-12 启动
  13. Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALL状态不明NCT05559450牵头方II期2022-02 启动
  14. CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL进行中,不再招募NCT05470777牵头方II期2020-01 启动
  15. Study of IFN-α Combined With CAR-T Cell Therapy in Relapsed and Refractory Acute Lymphoblastic Leukemia(R/R-ALL)状态不明NCT04534634牵头方II期2019-04 启动
  16. CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic Leukemia进行中,不再招募NCT03984968牵头方I/II期2017-07 启动
  17. CAR-T Cell Therapy Targeting to CD19 for R/R ALL进行中,不再招募NCT03919240牵头方I/II期2015-12 启动
  18. RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.正在招募NCT06250959牵头方(推断)II期2024-02 启动
  19. Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALL已完成NCT05557110牵头方(推断)II期2022-09 启动
  20. A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL进行中,不再招募NCT04521231研究中心I/II期2021-01 启动
  21. CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.状态不明NCT03614858研究中心I/II期2017-09 启动
  22. Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)已完成NCT03476239研究中心III期2017-10 启动
  23. CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia状态不明NCT03064269研究中心I期2017-03 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

再生障碍性贫血

Aplastic anaemia

2021–2025 年中国大陆作者发表的 412 篇再生障碍性贫血 PubMed 英文论文中,这家医院牵头了 11 篇,占 2.7%。

牵头论文
11
2021–2025 年
牵头试验
3
任何状态,ClinicalTrials.gov
牵头的开放试验
2
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 5520212022: 3320222023: 0020232024: 3320242025: 002025

苏州有 3 家医院列在再生障碍性贫血下全国有 63 家医院列在再生障碍性贫血下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA
    分期
    II期
    开始
    2026-01
    登记号
    NCT07400341

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:苏州大学附属第一医院苏州

  2. 正在招募
    A Multicenter, Randomized, Open-Label Study of Haplo-Cord HSCT for the Treatment of Aplastic Anemia
    分期
    不分期
    开始
    2025-10
    登记号
    NCT07499284

    年龄 14 岁 至 未注明(登记的条件)

    牵头:苏州大学附属第一医院;另有 2 家列出的医院为研究中心徐州、杭州、苏州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题干细胞移植免疫抑制治疗儿童
牵头的论文11
  1. Comparison of efficacy of eltrombopag combined with immunosuppression in the treatment of severe aplastic anemia and very severe aplastic anemia: real-world data and evidence.2024Annals of hematology
  2. First-line treatment of severe aplastic anemia: immunosuppressive therapy plus eltrombopag versus haploidentical hematopoietic stem cell transplantation, a multicenter prospective study.2024Bone marrow transplantation
  3. The Role of Pre-existing Anti-HLA Antibodies in Severe Aplastic Anemia Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation.2024Transplantation and cellular therapy
  4. Severe aplastic anemia patients with infection who received an allogeneic hematopoietic stem cell transplantation had a better chance: Long-term outcomes of a multicenter study.2022Frontiers in immunology免费全文
  5. Comparison of Haploidentical Hematopoietic Stem Cell Transplant With or Without Unrelated Cord Blood Infusion in Severe Aplastic Anemia: Outcomes of a Multicenter Study.2022Frontiers in immunology免费全文
  6. Matched related transplantation versus immunosuppressive therapy plus eltrombopag for first-line treatment of severe aplastic anemia: a multicenter, prospective study.2022Journal of hematology & oncology免费全文
  7. Lessons from a patient with severe aplastic anemia complicated with COVID-19.2021Asian journal of surgery免费全文
  8. Outcomes of severe aplastic anemia patients with infection proceeding with allogeneic hematopoietic stem cell transplantation, versus patients without infection.2021Bone marrow transplantation
  9. A comparative study of porcine antihuman lymphocyte globulin versus antithymocyte globulin-fresenius in an allogeneic hematopoietic cell transplantation conditioning regimen for severe aplastic anemia.2021Hematology (Amsterdam, Netherlands)
  10. Comparison of 2 Different Rabbit Anti-Thymocyte Globulin (r-ATG) Preparations: Thymocyte r-ATG versus T Lymphoblast Cell Line r-ATG in Allogeneic Hematopoietic Stem Cell Transplantation for Acquired Severe Aplastic Anemia: Propensity Score-2021Transplantation and cellular therapy
  11. First-Line Unrelated Double-Unit Umbilical Cord Blood Transplantation for Acquired Severe Aplastic Anemia.2021Transplantation proceedings
中文论文(未计入)3
  1. [The effect of cytomegalovirus and EB virus activation on hematopoietic reconstitution after intensive immunosuppressive therapy for severe aplastic anemia].2025Zhonghua nei ke za zhi
  2. [Positive rates and distribution characteristics of pre-existing anti-human-leukocyte-antigen antibodies in patients with different hematological diseases].2024Zhonghua yi xue za zhi
  3. [Sibling hematopoietic stem cell transplantation for treatment of severe aplastic anemia complicated with antiphospholipid syndrome: a case report].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA正在招募NCT07400341牵头方II期2026-01 启动
  2. A Multicenter, Randomized, Open-Label Study of Haplo-Cord HSCT for the Treatment of Aplastic Anemia正在招募NCT07499284牵头方不分期2025-10 启动
  3. GVHD Prophylaxis by Addition of CD20 Monoclonal Antibody to the Conditioning Regimen in SAA With Treatment of Allo-HSCT状态不明NCT05510505牵头方II期2021-12 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

噬血细胞性淋巴组织细胞增生症

Haemophagocytic lymphohistiocytosis

2021–2025 年中国大陆作者发表的 399 篇噬血细胞性淋巴组织细胞增生症 PubMed 英文论文中,这家医院牵头了 6 篇,占 1.5%。

牵头论文
6
2021–2025 年
牵头试验
3
任何状态,ClinicalTrials.gov
牵头的开放试验
2
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 2220232024: 3320242025: 112025

苏州有 2 家医院列在噬血细胞性淋巴组织细胞增生症下全国有 66 家医院列在噬血细胞性淋巴组织细胞增生症下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma
    分期
    IV期
    开始
    2025-11
    登记号
    NCT07270835

    年龄 14 岁 至 80 岁(登记的条件)

    牵头:苏州大学附属第一医院苏州

  2. 即将招募
    Dose-modified Emapalumab and Ruxolitinib (E-Ru) Regimens for Hemophagocytic Lymphohistiocytosis
    分期
    II/III期
    开始
    2025-06
    登记号
    NCT06951971

    年龄 1 岁 至 70 岁(登记的条件)

    牵头:苏州大学附属第一医院苏州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题治疗方案EB病毒与感染诱因干细胞移植
牵头的论文6
  1. Low-dose emapalumab combined with chemotherapy for adult patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.2025Transplant immunology
  2. Combined emapalumab and ruxolitinib in patients with haemophagocytic Lymphohistiocytosis.2024Blood cancer journal免费全文
  3. Myelodysplastic syndrome associated-haemophagocytic lymphohistiocytosis: A retrospective study of 15 cases in a single centre.2024British journal of haematology
  4. Successful Treatment of Refractory EBV-Associated Hemophagocytic Lymphohistiocytosis with Combined Emapalumab and PD-1 Blockade.2024Journal of clinical immunology
  5. An analysis of sintilimab combined with ruxolitinib as compassionate therapy for 12 adults with EBV-associated hemophagocytic lymphohistiocytosis.2023Annals of hematology
  6. Dose-escalating ruxolitinib for refractory hemophagocytic lymphohistiocytosis.2023Frontiers in immunology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. Dose-modified Emapalumab and Ruxolitinib (E-Ru) Regimens for Hemophagocytic Lymphohistiocytosis即将招募NCT06951971牵头方II/III期2025-06 启动
  2. Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma正在招募NCT07270835牵头方IV期2025-11 启动
  3. Programmed Cell Death Protein-1 (PD-1) Monoclonal Antibody for EBV-HLH and CAEBV as First-line Therapy状态不明NCT05039580牵头方IV期2021-05 启动
PubMed 以外找到的论文(未计入)5
  1. Endothelial Activation and Stress Index (EASIX) to Predict Survival in T or NK Cell Lymphoma-Associated Hemophagocytic Lymphohistiocytosis2024Blood会议摘要
  2. Pathological Subtyping, Outcomes, and Survival Trends of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: A Multicenter Analysis of 464 Patients2024Blood会议摘要
  3. Myelodysplastic Syndrome Associated Hemophagocytic Lymphohistiocytosis: A Retrospective Study of 15 Cases in a Single Center2023Blood会议摘要
  4. The Clinical Significance and Prognostic Value of Serum Beta-2 Microglobulin in Adult Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: A Multicenter Analysis of 326 Patients2023Blood会议摘要
  5. Additional file 2 of NBAS, a gene involved in cytotoxic degranulation, is recurrently mutated in pediatric hemophagocytic lymphohistiocytosis2022TigerPrints (Clemson University)论文

打开 PubMed 检索ClinicalTrials.gov

血液疾病

β 地中海贫血

Beta thalassaemia

2021–2025 年中国大陆作者发表的 312 篇β 地中海贫血 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

苏州有 1 家医院列在β 地中海贫血下全国有 133 家医院列在β 地中海贫血下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的β 地中海贫血开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血友病 A

Haemophilia A

2021–2025 年中国大陆作者发表的 272 篇血友病 A PubMed 英文论文中,这家医院牵头了 6 篇,占 2.2%。

牵头论文
6
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 3320222023: 1120232024: 1120242025: 112025

苏州有 2 家医院列在血友病 A下全国有 132 家医院列在血友病 A下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs
    分期
    II/III期
    开始
    2024-01
    登记号
    NCT06111638

    年龄 18 岁 至 未注明;仅男性(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心北京、天津、广州、成都、昆明、武汉、苏州、西安、贵阳、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录

这些论文过半是实验室或动物研究。

牵头的论文6
  1. Macrophage membrane-encapsulated miRNA nanodelivery system for the treatment of hemophilic arthritis.2025Journal of controlled release : official journal of the Controlled Release Society
  2. Incidence of deep venous thrombosis in patients with hemophilia undergoing bilateral simultaneous total knee arthroplasty: a retrospective cohort study.2024BMC musculoskeletal disorders
  3. Safety and efficacy of an anti-human APC antibody for prophylaxis of congenital factor deficiencies in preclinical models.2023Blood
  4. Blocking human protein C anticoagulant activity improves clotting defects of hemophilia mice expressing human protein C.2022Blood advances
  5. The coexistence of antiβ2 glycoprotein 1 antibody antibody has no effect on hemophilia A patient.2022Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
  6. No Benefit to Platelet-rich Plasma Over Placebo Injections in Terms of Pain or Function in Patients with Hemophilic Knee Arthritis: A Randomized Trial.2022Clinical orthopaedics and related researchRCT
早期论文(2016–2020 年)1
  1. Refractory lupus nephropathy and acquired Factor VIII and IX deficiencies in a patient with systemic lupus erythematosus treated with rituximab.2017Haemophilia : the official journal of the World Federation of Hemophilia
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
  1. Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs正在招募NCT06111638研究中心II/III期2024-01 启动
  2. A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A已完成NCT05707351研究中心III期2023-03 启动
  3. Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein已完成NCT06142552研究中心III期2023-12 启动
  4. Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10)已完成NCT05082116研究中心III期2021-09 启动
  5. A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors已完成NCT05053139研究中心III期2021-12 启动
  6. A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A已完成NCT04565236研究中心IV期2020-09 启动
  7. PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A已完成NCT02492984研究中心IV期2015-04 启动
  8. China ADVATE PTP Study已完成NCT02170402研究中心IV期2014-06 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血栓性血小板减少性紫癜

Thrombotic thrombocytopenic purpura

2021–2025 年中国大陆作者发表的 64 篇血栓性血小板减少性紫癜 PubMed 英文论文中,这家医院牵头了 5 篇,占 7.8%。

牵头论文
5
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 2220222023: 2220232024: 0020242025: 002025

苏州有 1 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Construction of a Database for TTP
    分期
    未注明
    开始
    2022-10
    登记号
    NCT05571774

    年龄未注明(登记的条件)

    牵头:苏州大学附属第一医院苏州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
牵头的论文5
  1. Association between N-acetylcysteine treatment and in-hospital mortality in adult patients with acquired thrombotic thrombocytopenic purpura: a cohort study.2023Annals of hematology
  2. Efficacy and safety of caplacizumab in the treatment of thrombotic thrombocytopenic purpura: a systematic review and meta-analysis.2023Expert review of hematology
  3. Bortezomib, a promising alternative for patients with refractory or relapsed thrombotic thrombocytopenic purpura after rituximab treatment.2022British journal of haematology
  4. Prognostic value of dynamic cardiac biomarkers in patients with acquired refractory thrombocytopenic purpura: A retrospective study in Chinese population.2022Journal of clinical laboratory analysis
  5. Clinical characteristics and outcomes of adult patients with acquired thrombotic thrombocytopenic purpura: a single center retrospective study.2021Annals of palliative medicine
中文论文(未计入)5
  1. [The combined regimen based on obinutuzumab plus glucocorticoid for 4 cases of relapsed iTTP].2025Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  2. [Relapsed immune thrombotic thrombocytopenic purpura secondary to systemic lupus erythematosus: a case report and literature review].2024Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  3. [A combined regimen based on bortezomib and glucocorticoids for 6 patients with recurrent/refractory immune thrombotic thrombocytopenic purpura].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  4. [Clinical diagnosis and treatment of hereditary thrombocytopenia and purpura: a report of five cases and literature review].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  5. [Research Advance in Treatment of Thrombotic Thrombocytopenic Purpura --Review].2022Zhongguo shi yan xue ye xue za zhi
早期论文(2016–2020 年)5
  1. Novel mutations in ADAMTS13 CUB domains cause abnormal pre-mRNA splicing and defective secretion of ADAMTS13.2020Journal of cellular and molecular medicine
  2. [Effect of Recombinant Protein in the Spacer Domain on ADAMTS13 Activity].2019Zhongguo shi yan xue ye xue za zhi
  3. [Research Advances of Acquired Thrombotic Thrombocytopenic Purpura--Review].2018Zhongguo shi yan xue ye xue za zhi
  4. [The diagnostic value of PLASMIC score in the discrimination between thrombotic thrombocytopenic purpura and disseminated intravascular coagulation].2018Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  5. [Progress of acquired thrombotic thrombocytopenic purpura].2017Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Construction of a Database for TTP正在招募NCT05571774牵头方2022-10 启动
  2. A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura进行中,不再招募NCT04683003研究中心III期2021-04 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

视神经脊髓炎谱系疾病

Neuromyelitis optica spectrum disorder

2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 10 篇,占 2.1%。

牵头论文
10
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 3320222023: 2220232024: 3320242025: 112025

苏州有 1 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的视神经脊髓炎谱系疾病开放试验。

这些数字背后的记录
研究主题生物制剂影像预防复发
论文中的科室神经内科影像/核医学科神经外科
牵头的论文10
  1. Exploring the causal role of gut microbiota and inflammatory proteins in neuromyelitis optica spectrum disorder: A Mendelian randomization study with mediation analysis.2025Medicine免费全文
  2. Correlation of GABA+ levels in the medial prefrontal cortex and circulating follicular helper T cells in neuromyelitis optica spectrum disorder patients with cognitive impairment.2024Brain and behavior免费全文
  3. Vitamin D status and neuromyelitis optica spectrum disease: A systematic review and meta-analysis.2024Clinical neurology and neurosurgery
  4. Aberrant hippocampal intrinsic morphological connectivity patterns in Neuromyelitis optica spectrum disorder with cognitive impairment: Insights from an individual-based morphological brain network.2024Multiple sclerosis and related disorders
  5. Different monoclonal antibodies and immunosuppressants administration in patients with neuromyelitis optica spectrum disorder: a Bayesian network meta-analysis.2023Journal of neurology免费全文
  6. B-cell proliferation characteristics and monitoring significance under the modified reduced-dose rituximab regimen for NMOSD: A real-world case series study.2023Multiple sclerosis and related disorders
  7. Different doses of Rituximab for the therapy of Neuromyelitis optica spectrum disorder: A systematic review and meta-analysis.2022Multiple sclerosis and related disorders
  8. Altered functional connectivity associated with cognitive impairment in neuromyelitis optica spectrum disorder.2022Multiple sclerosis and related disorders
  9. Reduced GABA levels in the medial prefrontal cortex are associated with cognitive impairment in patients with NMOSD.2022Multiple sclerosis and related disorders
  10. Efficacy and safety of modified reduced-dose rituximab in Chinese patients with neuromyelitis optica spectrum disorder: A retrospective cohort study.2021Journal of the neurological sciences
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases已撤回NCT06869278研究中心I期2025-06 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

重症肌无力

Myasthenia gravis

2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 9 篇,占 1.8%。

牵头论文
9
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 2220222023: 2220232024: 3320242025: 112025

苏州有 1 家医院列在重症肌无力下全国有 89 家医院列在重症肌无力下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Myasthenia Gravis Registry in China
    分期
    未注明
    开始
    2024-02
    登记号
    NCT06241521

    年龄未注明(登记的条件)

    牵头:复旦大学附属华山医院;另有 15 家列出的医院为研究中心上海、北京、南昌、天津、广州、徐州、成都、苏州、西安、郑州、重庆、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题抗体与诊断生物制剂与补体抑制剂常规免疫治疗
论文中的科室神经内科神经外科风湿免疫科
牵头的论文9
  1. Relative change rate of anti-acetylcholine receptor antibodies concentration Correlates with the recurrence of myasthenia gravis in AChR-Abs-positive patients.2025Clinica chimica acta; international journal of clinical chemistry
  2. Expression of lymphocyte activation gene-3 on CD4+T cells is regulated by cytokine interleukin-18 in myasthenia gravis.2024Journal of neuroimmunology
  3. The efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: a systematic review and meta-analysis.2024Journal of neurology
  4. Neurometabolic and Brain Functional Alterations Associated with Cognitive Impairment in Patients with Myasthenia Gravis: A Combined 1H-MRS and fMRI Study.2024Neuroscience
  5. Efficacy and safety of the innovative monoclonal antibodies in adults with generalized myasthenia gravis: a Bayesian network analysis.2023Frontiers in immunology免费全文
  6. Association between myasthenia gravis and cognitive disorders: a PRISMA-compliant meta-analysis.2023The International journal of neuroscience
  7. Clinical Significance of OX40 and OX40 Ligand in the Peripheral Blood of Patients with Myasthenia Gravis.2022Journal of immunology research免费全文
  8. Effect of tacrolimus on soluble costimulatory molecules in patients with refractory myasthenia gravis.2022Journal of neuroimmunology
  9. Primary biliary cirrhosis associated with myasthenia gravis after postpartum: a case report.2021Journal of medical case reports免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. Myasthenia Gravis Registry in China正在招募NCT06241521研究中心2024-02 启动
  2. A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases已撤回NCT06869278研究中心I期2025-06 启动
  3. Study of Telitacicept in Generalized Myasthenia Gravis已完成NCT05737160研究中心III期2023-03 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

烟雾病

Moyamoya disease

2021–2025 年中国大陆作者发表的 356 篇烟雾病 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.8%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 0020232024: 1120242025: 002025

苏州有 1 家医院列在烟雾病下全国有 47 家医院列在烟雾病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
    分期
    未注明
    开始
    2026-08
    登记号
    NCT07894107

    年龄 12 岁 至 70 岁(登记的条件)

    牵头:首都医科大学附属北京天坛医院;另有 12 家列出的医院为研究中心上海、北京、南昌、成都、杭州、武汉、苏州、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题遗传血管重建手术影像与脑血流
论文中的科室神经外科影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肝豆状核变性

Wilson disease

2021–2025 年中国大陆作者发表的 201 篇肝豆状核变性 PubMed 英文论文中,这家医院牵头了 2 篇,占 1.0%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

苏州有 1 家医院列在肝豆状核变性下全国有 28 家医院列在肝豆状核变性下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的肝豆状核变性开放试验。

这些数字背后的记录
研究主题遗传学(ATP7B)肝病与肝移植

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.3%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 1120242025: 112025

苏州有 3 家医院列在特发性肺纤维化下全国有 288 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录
论文中的科室病理/检验科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

苏州有 1 家医院列在肌萎缩侧索硬化症下全国有 182 家医院列在肌萎缩侧索硬化症下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis
    分期
    I/II期
    开始
    2026-06
    登记号
    NCT06726577

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心苏州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

脊髓性肌萎缩症

Spinal muscular atrophy

2021–2025 年没有牵头脊髓性肌萎缩症的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

苏州有 2 家医院列在脊髓性肌萎缩症下全国有 49 家医院列在脊髓性肌萎缩症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊髓性肌萎缩症开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Adult Spinal Muscular Atrophy (SMA) China Registry进行中,不再招募NCT05618379研究中心2023-01 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

法布雷病

Fabry disease

2021–2025 年中国大陆作者发表的 73 篇法布雷病 PubMed 英文论文中,这家医院牵头了 3 篇,占 4.1%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

苏州有 3 家医院列在法布雷病下全国有 80 家医院列在法布雷病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
    分期
    未注明
    开始
    2025-11
    登记号
    NCT07187440

    年龄 7 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 18 家列出的医院为研究中心北京、南京、合肥、哈尔滨、天津、太原、成都、杭州、汕头、深圳、石家庄、福州、苏州、西安

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

杜氏肌营养不良

Duchenne muscular dystrophy

2021–2025 年中国大陆作者发表的 213 篇杜氏肌营养不良 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.9%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 2220222023: 0020232024: 0020242025: 002025

苏州有 3 家医院列在杜氏肌营养不良下全国有 111 家医院列在杜氏肌营养不良下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年没有牵头白塞病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头

苏州有 3 家医院列在白塞病下全国有 139 家医院列在白塞病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
    分期
    III期
    开始
    2023-11
    登记号
    NCT06145893

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 20 家列出的医院为研究中心上海、临沂、北京、南昌、厦门、太原、广州、徐州、杭州、桂林、深圳、温州、石家庄、苏州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease正在招募NCT06145893研究中心III期2023-11 启动
  2. A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease已终止NCT04609397研究中心II期2020-11 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.3%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

苏州有 6 家医院列在IgA 肾病下全国有 300 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.7%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

苏州有 4 家医院列在原发性胆汁性胆管炎下全国有 153 家医院列在原发性胆汁性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。

这些数字背后的记录
论文中的科室风湿免疫科神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性硬化性胆管炎

Primary sclerosing cholangitis

2021–2025 年中国大陆作者发表的 100 篇原发性硬化性胆管炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.0%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

苏州有 1 家医院列在原发性硬化性胆管炎下全国有 89 家医院列在原发性硬化性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性硬化性胆管炎开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

苏州大学附属第一医院

First Affiliated Hospital of Soochow University

苏州

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR Wikidata
First Affiliated Hospital of Soochow University-; first Affiliated Hospital of Soochow University; China The First Affiliated Hospital of Soochow University; First Affiliated Hospital of Soochow University. Suzhou; Zhangjiagang First Affiliated Hospital of Soochow University

提出更正下载数据